arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Evommune, Inc.

EVMN Health Care Biotechnology: Pharmaceutical Preparations
$13.02
▲ +0.4% Today
as of Aug 5, 16:48 ET
Last 30 days -48.29% Jun 26 → Aug 05
$9.92 $14.02 $18.12 $22.21 $26.31 Jun 26 Jul 06 Jul 14 Jul 21 Jul 29 Aug 05
Open
$20.52
High
$21.23
Low
$19.59
Volume
$417,272
Avg Vol
$438,433
Mkt Cap
$417M
P/E (TTM)
—
Beta
—
52w High
$33.20
52w Low
$13.88
Div Yield
—
Shares Out
$36M

Recent Press Releases & News last 60 days · 6 items

Jul 30 · 12:00 PR Business Wire
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Jun 30 · 15:15 Zacks
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Jun 29 · 15:28 Clinical Trials Arena
Evommune terminates oral drug’s development in CSU
▸ Show all 6 press releases & news Free account →

Overview

52-week range
$14
$33
0% of range
Avg surprise (last 1)
+22.9%
Avg reaction (last 1)
-5.6%
0% positive
Latest IV / EM
130%
EM ±21.7% · $13 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-10.47$-8.01$-5.56$-3.10$-0.64 Actual $-10.47Actual $-9.48Actual $-8.07Actual $-0.64Est $-0.83 SepMarSepMar/2026
Revenue vs Net Income Revenue Net income
$-22M$-14M$-6M$2M$10M Sep 24Mar 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu May 7, 2026Mar/2026 $-0.64 $-0.83 +22.9% — -5.6% earnings
Tue Sep 30, 2025Sep 2025 $-8.07 — — — — financials
Mon Mar 31, 2025Mar 2025 $-9.48 — — — — financials
Mon Sep 30, 2024Sep 2024 $-10.47 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Aug 6, 2026Jun/2026OTHER -$0.68—

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Mar 2025Dec 2024Sep 2024
Revenue$0—$10M$3M——
Cost of revenue——————
Gross profit——————
Operating income$-24M—$-13M$-15M—$-17M
Net income$-22M—$-12M$-15M—$-16M
EPS (diluted)$-0.64—$-8.07$-9.48—$-10.47

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$48M$44M$27M$6M$16M$18M
Inventory——————
Total current assets$216M$153M$82M—$74M—
Total assets$322M$225M$85M—$76M—
Long-term debt——————
Total liabilities$18M$19M$11M—$29M—
Total equity$305M$206M$-183M$-158M$-144M$-123M

Implied volatility — last 90 days

20%158%297%435%573% Jun 08 — IV 191% · EM ±25.3%Jun 17 — IV 574% · EM ±24.0%Jun 19 — IV 245% · EM ±54.1%Jun 22 — IV 267% · EM ±55.7%Jun 23 — IV 270% · EM ±55.3%Jun 24 — IV 257% · EM ±51.6%Jun 25 — IV 279% · EM ±54.7%Jun 26 — IV 267% · EM ±51.0%Jun 29 — IV 100% · EM ±17.7%Jun 30 — IV 123% · EM ±21.2%Jul 01 — IV 157% · EM ±26.2%Jul 02 — IV 149% · EM ±24.1%Jul 03 — IV 154% · EM ±24.1%Jul 06 — IV 196% · EM ±27.1%Jul 07 — IV 163% · EM ±21.6%Jul 08 — IV 39% · EM ±4.9%Jul 09 — IV 28% · EM ±3.3%Jul 10 — IV 20% · EM ±2.2%Jul 13 — IV 114% · EM ±9.5%Jul 14 — IV 144% · EM ±10.4%Jul 15 — IV 88% · EM ±5.2%Jul 16 — IV 368% · EM ±15.4%Jul 20 — IV 59% · EM ±13.9%Jul 21 — IV 192% · EM ±44.6%Jul 22 — IV 160% · EM ±36.6%Jul 23 — IV 153% · EM ±34.5%Jul 24 — IV 132% · EM ±29.1%Jul 27 — IV 167% · EM ±34.9%Jul 28 — IV 239% · EM ±48.9%Jul 29 — IV 226% · EM ±45.2%Jul 30 — IV 196% · EM ±38.3%Jul 31 — IV 232% · EM ±44.4%Aug 03 — IV 212% · EM ±37.5%Aug 04 — IV 137% · EM ±23.6%Aug 05 — IV 130% · EM ±21.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,164.75-0.4%
JNJ
Johnson & Johnson
$624.1B $258.23+0.2%
ABBV
AbbVie Inc.
$454.8B $246.35+0.1%
MRK
Merck & Company, Inc.
$321.6B $129.20+0.7%
PM
Philip Morris International Inc
$299.3B $188.93-0.0%
NVS
Novartis AG
$297.9B $154.440.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in